JP2023546362A5 - - Google Patents
Info
- Publication number
- JP2023546362A5 JP2023546362A5 JP2023521357A JP2023521357A JP2023546362A5 JP 2023546362 A5 JP2023546362 A5 JP 2023546362A5 JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023546362 A5 JP2023546362 A5 JP 2023546362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- cancer
- acceptable salt
- pharmaceutical
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089195P | 2020-10-08 | 2020-10-08 | |
| US63/089,195 | 2020-10-08 | ||
| PCT/EP2021/077703 WO2022074124A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546362A JP2023546362A (ja) | 2023-11-02 |
| JP2023546362A5 true JP2023546362A5 (cg-RX-API-DMAC7.html) | 2024-09-20 |
| JP7818585B2 JP7818585B2 (ja) | 2026-02-20 |
Family
ID=78293953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521357A Active JP7818585B2 (ja) | 2020-10-08 | 2021-10-07 | 癌を治療するための組み合わせ療法 |
Country Status (19)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| WO2023036285A1 (zh) * | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| US20230250428A1 (en) * | 2022-02-07 | 2023-08-10 | Alliance Of Cardiovascular Researchers | Method and composition for early detection of malignancies |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| CA3254948A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Polytherapy for the treatment of cancer |
| CN121464135A (zh) * | 2023-07-07 | 2026-02-03 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6648040B2 (ja) * | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用 |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2021
- 2021-10-06 TW TW110137116A patent/TW202228693A/zh unknown
- 2021-10-07 AU AU2021356123A patent/AU2021356123B2/en active Active
- 2021-10-07 BR BR112023005160A patent/BR112023005160A2/pt unknown
- 2021-10-07 ES ES21794474T patent/ES3005507T3/es active Active
- 2021-10-07 JP JP2023521357A patent/JP7818585B2/ja active Active
- 2021-10-07 DK DK21794474.3T patent/DK4225297T3/da active
- 2021-10-07 CA CA3197056A patent/CA3197056A1/en active Pending
- 2021-10-07 HU HUE21794474A patent/HUE069249T2/hu unknown
- 2021-10-07 PT PT217944743T patent/PT4225297T/pt unknown
- 2021-10-07 EP EP21794474.3A patent/EP4225297B1/en active Active
- 2021-10-07 WO PCT/EP2021/077703 patent/WO2022074124A1/en not_active Ceased
- 2021-10-07 KR KR1020237013320A patent/KR20230083291A/ko active Pending
- 2021-10-07 MX MX2023004156A patent/MX2023004156A/es unknown
- 2021-10-07 IL IL301687A patent/IL301687A/en unknown
- 2021-10-07 CN CN202180065599.5A patent/CN116194110B/zh active Active
- 2021-10-07 FI FIEP21794474.3T patent/FI4225297T3/fi active
- 2021-10-07 US US18/248,108 patent/US20230372333A1/en active Pending
- 2021-10-07 PL PL21794474.3T patent/PL4225297T3/pl unknown
-
2023
- 2023-05-04 ZA ZA2023/04965A patent/ZA202304965B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| Mjos et al. | Metallodrugs in medicinal inorganic chemistry | |
| Hartinger et al. | KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients | |
| FI4225297T3 (fi) | Yhdistelmälääkehoito syövän hoidossa | |
| US20230398119A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| CN109069500B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| US9370535B2 (en) | Method for treatment of advanced solid tumors | |
| JP2003533485A5 (cg-RX-API-DMAC7.html) | ||
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| Higuchi et al. | A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501) | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| ES2299841T3 (es) | Composiciones farmaceuticas que comprenden azd2171 y zd6126, y usos de los mismos. | |
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| Malviya et al. | Advances in Metallodrug-driven Combination Therapy for Treatment of Cancer | |
| CN105263499B (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| US9114149B2 (en) | [CU(thp)4]n[X]-n compounds for the treatment of a broad range of human solid tumors, including refractory tumors | |
| KR20060130764A (ko) | 병용 요법 | |
| JP2024520307A5 (cg-RX-API-DMAC7.html) | ||
| JP2007508331A (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| CN106038571B (zh) | 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用 | |
| CN110787303A (zh) | 一种Pt与巯基化合物的加合物Pt-SR、制备及应用 | |
| RU2026101563A (ru) | Способы лечения пациентов с немелкоклеточным раком легких, имеющих аберрацию в гене egfr |